Home > Publications > Disease Control Priorities in Developing Countries >

5. Science and Technology for Disease Control: Past, Present, and Future

Table 5.2: Estimated Global Health Research and Development Funding for 1998

Estimated Global Health Research and Development Funding for 1998
Type of funding	Total (US$ billions)	Percentage
Public funding: high-income and transition countries	34.5	47
Private funding: pharmaceutical industry	30.5	42
Private not-for-profit funding	6.0	8
Public funding: low- and middle-income countries	2.5	3
Total	73.5	100

Source: WHO 2002b.

< Back to Chapter Summary Page

Chapter Sections

Figures

5.1 Effects of a One-Hour Streptokinase Infusion Together with Aspirin for One Month on the 35-Day Mortality in the Second International Study of Infarct Survival Trial among 17,187 Patients with Acute Myocardial Infarction Who Would Not Normally Have Received Streptokinase or Aspirin, Divided at Random into Four Groups to Receive Aspirin Only, Streptokinase Only, Both, or Neither
5.2 Decline in Serious Forms of Thalassemia in Different Populations after the Initiation of Prenatal Diagnosis in 1972 following the Development of North-South Partnerships.

Boxes

5.1 Chronic Myeloid Leukemia: The Path from Basic Science to the Clinic

Tables

© 2006 The World Bank Group, All Rights Reserved.